Financial Ratios Recursion Pharmaceuticals, Inc.
Equities
RXRX
US75629V1044
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
Pre-market 12:52:25 | |||
6.910 USD | +2.22% | 7.190 | +4.05% |
09-03 | Jefferies Cuts Price Target on Recursion Pharmaceuticals to $6 From $8, Maintains Hold Rating | MT |
09-03 | Recursion Pharmaceuticals Says REC-994 Phase 2 Trial Shows Safety and Efficacy Trends | MT |
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -26.24 | -25.14 | -23.42 | -32.29 |
Return on Total Capital | - | -30.53 | -28.62 | -28.43 | -41.64 |
Return On Equity % | - | -54.57 | -47.51 | -46.56 | -69.12 |
Return on Common Equity | - | 52.64 | -110.79 | -46.56 | -69.12 |
Margin Analysis | |||||
Gross Profit Margin % | -1.88K | -1.5K | -1.23K | -411.94 | -536.71 |
SG&A Margin | 817.21 | 621.3 | 566.73 | 204.8 | 248.62 |
EBITDA Margin % | -2.54K | -2.02K | -1.71K | -587.23 | -730.58 |
EBITA Margin % | -2.69K | -2.13K | -1.79K | -615.79 | -766.26 |
EBIT Margin % | -2.69K | -2.12K | -1.8K | -616.74 | -785.33 |
Income From Continuing Operations Margin % | -2.67K | -2.2K | -1.83K | -601.05 | -735.99 |
Net Income Margin % | -2.67K | -2.2K | -1.83K | -601.05 | -735.99 |
Net Avail. For Common Margin % | -2.67K | -2.2K | -1.83K | -601.05 | -735.99 |
Normalized Net Income Margin | -1.65K | -1.35K | -1.14K | -375.66 | -465.69 |
Levered Free Cash Flow Margin | - | -940.21 | -1.2K | -264.55 | -420.34 |
Unlevered Free Cash Flow Margin | - | -918.76 | -1.18K | -264.47 | -420.21 |
Asset Turnover | |||||
Asset Turnover | - | 0.02 | 0.02 | 0.06 | 0.07 |
Fixed Assets Turnover | - | 0.16 | 0.22 | 0.43 | 0.37 |
Receivables Turnover (Average Receivables) | - | 25.81 | 107.14 | - | - |
Short Term Liquidity | |||||
Current Ratio | 11.43 | 11.67 | 11.46 | 5.68 | 4.7 |
Quick Ratio | 10.48 | 11.35 | 11.27 | 5.51 | 4.24 |
Operating Cash Flow to Current Liabilities | -8.53 | -1.97 | -3.4 | -0.83 | -3.09 |
Days Sales Outstanding (Average Receivables) | - | 14.18 | 3.41 | - | - |
Average Days Payable Outstanding | - | 6.75 | 5.25 | 6.63 | 5.49 |
Long Term Solvency | |||||
Total Debt/Equity | 16.26 | 5.16 | 0.13 | 10.5 | 10.93 |
Total Debt / Total Capital | 13.99 | 4.91 | 0.13 | 9.5 | 9.86 |
LT Debt/Equity | 16.16 | 4.72 | 0.12 | 9.25 | 9.61 |
Long-Term Debt / Total Capital | 13.9 | 4.48 | 0.12 | 8.37 | 8.66 |
Total Liabilities / Total Assets | 24.24 | 18.94 | 11.04 | 30.73 | 29.11 |
EBIT / Interest Expense | -98.33 | -61.74 | -61.92 | -4.47K | -3.61K |
EBITDA / Interest Expense | -92.75 | -58.85 | -59.07 | -4.09K | -3.25K |
(EBITDA - Capex) / Interest Expense | -98.91 | -63.13 | -72.55 | -4.77K | -3.37K |
Total Debt / EBITDA | -0.21 | -0.16 | -0 | -0.23 | -0.16 |
Net Debt / EBITDA | 0.97 | 3.12 | 2.96 | 2.22 | 1.08 |
Total Debt / (EBITDA - Capex) | -0.2 | -0.15 | -0 | -0.19 | -0.15 |
Net Debt / (EBITDA - Capex) | 0.91 | 2.91 | 2.41 | 1.9 | 1.04 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | 70.85 | 156.89 | 291.46 | 11.88 |
Gross Profit, 1 Yr. Growth % | - | 36.48 | 110.75 | 31.2 | 45.76 |
EBITDA, 1 Yr. Growth % | - | 34.74 | 116.15 | 34.18 | 39.19 |
EBITA, 1 Yr. Growth % | - | 34.21 | 115.97 | 34.46 | 39.21 |
EBIT, 1 Yr. Growth % | - | 34.48 | 116.01 | 34.44 | 42.46 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 40.61 | 114.33 | 28.42 | 36.99 |
Net Income, 1 Yr. Growth % | - | 40.61 | 114.33 | 28.42 | 36.99 |
Normalized Net Income, 1 Yr. Growth % | - | 39.39 | 115.57 | 28.99 | 38.69 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 39.24 | -62.7 | -8.3 | 15.69 |
Accounts Receivable, 1 Yr. Growth % | - | 3.31 | -78.21 | - | - |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 6.55 | 149.26 | 87.64 | -1.05 |
Total Assets, 1 Yr. Growth % | - | 194.37 | 104.41 | 14.9 | -6.79 |
Tangible Book Value, 1 Yr. Growth % | - | 68.01 | -359.01 | -10.55 | -22.49 |
Common Equity, 1 Yr. Growth % | - | 66.01 | -363.19 | -10.52 | -4.6 |
Cash From Operations, 1 Yr. Growth % | - | -20.41 | 249.38 | -47.34 | 244.55 |
Capital Expenditures, 1 Yr. Growth % | - | 49.13 | 582.52 | -6.88 | -67.74 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 252.29 | -13.55 | 77.76 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 255.7 | -12.26 | 77.76 |
Compound Annual Growth Rate Over Two Years | |||||
Total Revenues, 2 Yr. CAGR % | - | - | 109.5 | 217.12 | 109.27 |
Gross Profit, 2 Yr. CAGR % | - | - | 69.6 | 66.29 | 38.29 |
EBITDA, 2 Yr. CAGR % | - | - | 70.54 | 70.3 | 36.66 |
EBITA, 2 Yr. CAGR % | - | - | 70.95 | 70.41 | 36.82 |
EBIT, 2 Yr. CAGR % | - | - | 71.09 | 70.41 | 38.39 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 73.6 | 65.9 | 32.64 |
Net Income, 2 Yr. CAGR % | - | - | 73.6 | 65.9 | 32.64 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 73.99 | 66.75 | 33.75 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -27.95 | -41.56 | 3 |
Accounts Receivable, 2 Yr. CAGR % | - | - | -52.55 | - | - |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 62.97 | 116.26 | 36.26 |
Total Assets, 2 Yr. CAGR % | - | - | 145.3 | 53.25 | 3.49 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 108.6 | 52.21 | -16.73 |
Common Equity, 2 Yr. CAGR % | - | - | 109.03 | 53.46 | -7.61 |
Cash From Operations, 2 Yr. CAGR % | - | - | 66.75 | 35.64 | 34.7 |
Capital Expenditures, 2 Yr. CAGR % | - | - | 219.04 | 152.1 | -45.19 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 74.51 | 23.96 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 76.67 | 24.89 |
Compound Annual Growth Rate Over Three Years | |||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 158.04 | 124.07 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 55.69 | 59.14 |
EBITDA, 3 Yr. CAGR % | - | - | - | 57.44 | 59.23 |
EBITA, 3 Yr. CAGR % | - | - | - | 57.8 | 59.3 |
EBIT, 3 Yr. CAGR % | - | - | - | 57.88 | 60.53 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 57 | 55.65 |
Net Income, 3 Yr. CAGR % | - | - | - | 57 | 55.65 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 57.47 | 56.82 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -21.96 | -26.62 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 70.81 | 66.65 |
Total Assets, 3 Yr. CAGR % | - | - | - | 90.51 | 29.85 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 57.3 | 21.55 |
Common Equity, 3 Yr. CAGR % | - | - | - | 57.53 | 30.97 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 13.55 | 85.07 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 111.63 | 27.04 |
Levered Free Cash Flow, 3 Yr. CAGR % |